BioSight
Companies
X4 Pharmaceuticals, Inc logo

XFOR

NASDAQBOSTON, MA
X4 Pharmaceuticals, Inc

X4 Pharmaceuticals develops drugs that target chemokine receptors to treat immune and blood disorders. The company's lead product, XOLREMDI (mavorixafor), is an oral therapy that has received regulatory approval and is being commercialized. X4 is in the commercialization stage, though it faces typical biotech risks including capital requirements and the need to achieve sufficient revenue to sustain operations.

Price history not yet available for XFOR.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar